Philips’ (PHG) shares have gained 17.6% in the year-to-date period, outperforming the Zacks Medical sector’s growth of 4.3%. The company is benefiting from strong momentum in the Diagnosis & Treatment segment on the back of its strengthening Precision Diagnosis portfolio powered by artificial intelligence (AI). The company’s latest launch of an AI-enabled cardiovascular ultrasound platform testifies to the aforesaid fact. This FDA 510(k) cleared AI platform combines Philips’ EPIQ CVx and Affiniti CVx ultras ...